A novel locus on mouse chromosome 7 that influences survival after infection with tick-borne encephalitis virus

Martin Palus1,2†, Yahya Sohrabi3†, Karl W. Broman4, Hynek Strnad5, Matyáš Šíma3, Daniel Růžek1,2, Valeriya Volkova3, Martina Slapničková3, Jarmila Vojtišková3, Lucie Mrázková3,6, Jiří Salát2 and Marie Lipoldová3,6*

Abstract

Background: Tick-borne encephalitis (TBE) is the main tick-borne viral infection in Eurasia. Its manifestations range from inapparent infections and fevers with complete recovery to debilitating or fatal encephalitis. The basis of this heterogeneity is largely unknown, but part of this variation is likely due to host genetic. We have previously found that BALB/c mice exhibit intermediate susceptibility to the infection of TBE virus (TBEV), STS mice are highly resistant, whereas the recombinant congenic strain CcS-11, carrying 12.5% of the STS genome on the background of the BALB/c genome is even more susceptible than BALB/c. Importantly, mouse orthologs of human TBE controlling genes Oas1b, Cd209, Tlr3, Ccr5, Ifnl3 and Il10, are in CcS-11 localized on segments derived from the strain BALB/c, so they are identical in BALB/c and CcS-11. As they cannot be responsible for the phenotypic difference of the two strains, we searched for the responsible STS-derived gene-locus. Of course the STS-derived genes in CcS-11 may operate through regulating or epigenetically modifying these non-polymorphic genes of BALB/c origin.

Methods: To determine the location of the STS genes responsible for susceptibility of CcS-11, we analyzed survival of TBEV-infected F2 hybrids between BALB/c and CcS-11. CcS-11 carries STS-derived segments on eight chromosomes. These were genotyped in the F2 hybrid mice and their linkage with survival was tested by binary trait interval mapping. We have sequenced genomes of BALB/c and STS using next generation sequencing and performed bioinformatics analysis of the chromosomal segment exhibiting linkage with TBEV survival.

Results: Linkage analysis revealed a novel suggestive survival-controlling locus on chromosome 7 linked to marker D7Nds5 (44.2 Mb). Analysis of this locus for polymorphisms between BALB/c and STS that change RNA stability and genes’ functions led to detection of 9 potential candidate genes: Cd33, Klk1b22, Siglece, Klk1b16, Fut2, Grwd1, Abcc6, Otog, and Mkrn3. One of them, Cd33, carried a nonsense mutation in the STS strain.

Conclusions: The robust genetic system of recombinant congenic strains of mice enabled detection of a novel suggestive locus on chromosome 7. This locus contains 9 candidate genes, which will be focus of future studies not only in mice but also in humans.

Keywords: Tick-borne encephalitis virus (TBEV), Mouse model, Survival, Susceptibility locus, Chromosome 7, Candidate gene

*Correspondence: lipoldova@img.cas.cz
†Martin Palus and Yahya Sohrabi contributed equally to this work
3 Department of Molecular and Cellular Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 1083, 14220 Prague, Czech Republic
Full list of author information is available at the end of the article

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Tick-borne encephalitis (TBE) is the main tick-borne viral infection in Eurasia. It is prevalent across the entire continent from Japan to France [1]. The disease is caused by tick-borne encephalitis virus (TBEV), a flavivirus of the family Flaviviridae, which besides TBEV includes West Nile virus (WNV), dengue virus (DENV), Zika virus (ZIKV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), and several other viruses causing extensive morbidity and mortality in humans. Ticks act as both the vector and reservoir for TBEV. The main hosts are small rodents, with humans being accidental hosts. In Europe and Russia between 5000 and 13,000 clinical cases of TBE are reported annually, with a large annual fluctuation [2]. The highest incidence of TBE is reported in western Siberia, in the Czech Republic, Estonia, Slovenia and Lithuania, but the prevalence of the disease is believed to be higher than actually reported [1, 2]. TBEV may produce a variety of clinical symptoms, from an asymptomatic disease to a fever and acute or chronic progressive encephalitis. The outcome of infection depends on the strain of virus [1], as well as on the genotype [3], sex and age of the host [4], and on the environmental and social factors [1]. Environmental and social factors influence also risk of infection.

Genetic influence on susceptibility to TBEV-induced disease has been analyzed by two main strategies: a hypothesis-independent phenotype-driven approach and a hypothesis-driven approach. Application of a genome-wide search (hypothesis-independent approach) in mouse led to identification of the gene Oas1 (2'-5'-oligoadenylate synthetase gene) [5, 6]. A stop codon in exon 4 of the gene Oas1b (a natural knockout) present in majority of mouse laboratory strains causes production of protein lacking 30% of the C terminal sequence [5]. This part of molecule seems to be critical for tetramerization required for OAS1B activity leading to degradation of viral RNA. Thus, this mutation makes majority of mouse laboratory strains susceptible to flaviviruses [6, 7]. Human ortholog to this gene (OASI) also modifies susceptibility to other flaviviruses (WNV) [8, 9], whereas OAS2 and OAS3 localized in the same cluster on chromosome 12q24.2 influence response to TBEV [3]. The polymorphic sites associated in OAS2 and OAS3 with susceptibility to TBEV did not resulted in amino acid changes, thus mechanisms of susceptibility control is not known [3]. The hypothesis-driven approach has focused on genes that encode molecules indicated to be involved in antiviral response by mechanistic studies [9]. These candidate genes studies revealed that polymorphisms in CD209/Dc-SIGN [10], CCR5 [11, 12], TLR3 [12, 13], IL10 [14] and IFNL3/IL28B [14] influence susceptibility to TBEV in humans.

Our previous study has shown that both after subcutaneous and intracerebral inoculation of European prototypic TBEV, BALB/c mice exhibited intermediate susceptibility to the infection, STS mice were highly resistant, whereas the strain CcS-11, which carries 12.5% of the STS genome on the background of the genome of the strain BALB/c [15], is even more susceptible than its two parents—BALB/c and STS [16]. Importantly, mouse orthologs of human TBEV controlling genes: Oas1b, Cd209, Tlr3, Ccr5, Il10 and Ifnl3 are in CcS-11 localized on segments derived from the strain BALB/c (Fig. 1), so they are identical in both BALB/c and CcS-11 and hence cannot be responsible for the phenotypic difference of the two strains. Therefore, the difference must be due to a presently unknown locus, which could be detected by a linkage study of a cross between BALB/c and CcS-11. Thus, we have generated a F2 intercross between BALB/c and CcS-11 and performed a linkage and bioinformatics analysis. These studies revealed a novel suggestive locus on mouse chromosome 7 containing 9 potential candidate genes.

Methods

Mice

417 female F2 offspring of an intercross between strains CcS-11 and BALB/c (mean and median age 9.5 and 9 weeks, respectively, at the time of infection) were produced at the Institute of Molecular Genetics AS CR. Mice were tested in three successive experimental groups at the Institute of Parasitology, AS CR. When used for these experiments, strain CcS-11 had undergone more than 90 generations of inbreeding. Experiments Nr. 1, 2, and 3 comprised 120, 121 and 176 F2 mice, respectively. Sterilized pellet diet and water were supplied ad libitum. The mice were housed in plastic cages with wood-chip bedding, situated in a specific pathogen-free room with a constant temperature of 22 °C and a relative humidity of 65%.

Virus infection and disease phenotype

Experiments were performed with European prototypic TBEV strain Neudoerfl (a generous gift from Professor F. X. Heinz, Medical University of Vienna). This strain was passaged five times in brains of suckling mice before the use in this study [16]. Mice were infected subcutaneously with 10^4 pfu of the virus.

Mice were scored for mortality for a period of 35 days post-infection (p.i.) with TBEV, as well as presence of ruffled fur and paresis in three independent successive experiments at the Institute of Parasitology AS CR.
Genotyping of F2 mice
DNA was isolated from tails using a standard proteinase procedure. The strain CcS-11 differs from BALB/c at STS-derived regions on eight chromosomes [17]. These differential regions were genotyped in the F2 hybrid mice between CcS-11 and BALB/c using 16 microsatellite markers (Generi Biotech, Hradec Králové, Czech Republic): D1Mit403, D3Mit45, D7Mit25, D7Nds5, D7Mit18, D7Nds1, D7Mit282, D7Mit259, D8Mit85, D10 Mit12, D10Mit46, D12Mit37, D16Mit73, D19Mit51, D19Mit60, D19Mit46 (Fig. 1) as described in [17].

Statistical analysis
Survival, ruffled fur and paresis were treated as binary phenotypes (death/survival; presence/absence of symptom), and binary trait interval mapping was performed [18, 19]. A permutation test [20] was used to assess significance. This takes account of the limited genetic difference between the strains BALB/c and CcS-11. On the basis of 10,000 permutation replicates, the 5% significance LOD threshold was 2.56; the 10% threshold was 2.23. The Pearson correlation coefficient between presence of death and paresis was computed by the program Statistica for Windows 12.0 (StatSoft, Inc., Tulsa, OK).

Detection of polymorphisms that change RNA stability and genes' functions
We have sequenced the genomes of strains BALB/c and STS using next generation sequencing (NGS) system HiSeq 2500 (Illumina) (12 x coverage). NGS data was preprocessed using software Trimmomatic [21] and overlapped paired reads were joined by software Flash [22]. Alignment—reference mouse sequence mm10 (build GRCh38)—was performed using BWA (Burrows-Wheeler Aligner) [23] program. Mapped reads were sorted and indexed, duplicated reads were marked. Segment covering peak of linkage on chromosome 7 from 36.2 to 74.5 Mb was inspected for polymorphisms between BALB/c and STS that change RNA stability and
genes’ functions. Local realignment around indels, base recalibration and variants filtration were performed using software GATK (The Genome Analysis Toolkit) [24]. Variant annotation and effect prediction was performed by software SnpEff [25]. IGV (Integrated Genome Viewer) was used for visualization of results [26].

Results
Binary trait linkage analysis revealed a suggestive locus on chromosome 7 near D7Nds5 affecting the binary trait (death/survival) (LOD = 2.15), with a corresponding genome-scan-adjusted P value = 0.12 (Fig. 2a). The 1-LOD support interval spans from D7Mit25 to D7Nds1. The STS allele both in homozygotes and heterozygotes was associated with a higher death rate in each of the three separate experimental groups (Fig. 2b), and in the pooled data (Fig. 3a), so its presence in CcS-11 enhances even more the overall susceptibility determined by the BALB/c background. Ruffled fur was observed in only 8% of mice, so it was not suitable for statistical analysis. Paresis was less frequent than mortality (n = 60 vs. 102) and not all paretic mice died, but the two phenotypes were positively correlated (Pearson correlation 0.53). Moreover, frequency of paresis in the three D7Nds5 genotypes (Fig. 3b), although not significantly different, was biologically compatible with the survival data, because D7Nds5 CC homozygotes had the highest survival rate, and the lowest percentage of paresis.

We have sequenced genomes of BALB/c and STS and analyzed the segment covering peak of linkage on chromosome 7 from 36.2 to 74.5 Mb for polymorphisms between BALB/c and STS that change RNA stability and genes’ functions. This revealed 9 potential candidate genes: Cd33 (CD33 antigen), Klk1b22 (kallikrein 1-related peptidase b22), SiglecE (sialic acid binding Ig-like lectin E), Klk1b16 (kallikrein 1-related peptidase b16), Fut2 (fucosyltransferase 2), Grwd1 (glutamate-rich WD repeat containing 1), Abcc6 (ATP-binding cassette,
sub-family C (CFTR/MRP), member 6), Otog (otogelin), and Mkrn3 (makorin, ring finger protein, 3) (Table 1, Fig. 1).

One of these genes, Cd33, carried in the strain STS a nonsense mutation. Other changes in the strain STS in comparison with BALB/c (and the reference strain C57BL/6) represented single amino acids change in Siglec E, KLK1b22, KLK1b16, FUT2 and OTOG. The BALB/c strain had in comparison with STS (and the reference strain C57BL/6) deletion of two amino acids in GRWD1, insertion of four amino acids in MKRN3 and single amino acid change in and ABCC6 (Table 1).

**Discussion**

CD33 and Siglec E belong to family of CD33-related sialic-acid-binding immunoglobulin-like lectins (CD33r-Siglecs). They are ITIM-containing inhibitory receptors, which are involved in regulation of inflammatory and immune responses [27]. Gene Cd33 carried in the strain STS a nonsense mutation (Table 1). Product of this gene is in mouse expressed on myeloid precursors and cells of myeloid origin [28] and on microglial cells [29]. It can inhibit response to amyloid plaques and its deletion leads to protection in the mouse model of Alzheimer disease (AD) [29] and in humans some CD33 genetic variants are associated with late-onset AD [30]; its potential role in pathology of TBEV might be associated with its regulatory role in inflammatory responses. Gene SiglecE carried in the strain STS a single amino acid change. Siglec E is expressed on microglia and inhibits neurotoxicity triggered by neural debris [31], which might have protective role against damage induced by flaviviruses.

A single amino acid change was present in KLK1b22 and KLK1b16. Kallikreins are serine proteases that might both help to fight infection by activating complement system [32], as well as aggravate disease symptoms by releasing bradykinin, which causes alterations in vascular permeability [33]. Their role in defense against flaviviruses has not been described. Kallikrein-bradykinin system have been described to contribute to protection against Leishmania [34] and Trypanosoma cruzi [35] parasites in mice. Interestingly, on the mouse chromosome 7 were in the strain CcS-11 mapped loci Lmr21 and Tbr2r3 that control susceptibility to L. major [36] and T. b. brucei [17], respectively. However, both loci are mapped on a long chromosomal segment, thus other gene(s) might be responsible for their effect.

FUT2 have been described to influence control of a wide range of pathogens such as noroviruses [37], rotaviruses [38], HIV [39], and Escherichia coli [40] in humans, and to Helicobacter pylori in mouse [41], but its role in resistance to flaviviruses is not known.

Makorin 1 induces degradation of WNV capsid which might protect host cells [42]. The E3 ligase domain responsible for MKRN1 effect is present also in MKRN3 [43]. Thus, gene Mkrn3 might have relationship to defense against flaviviruses. Similarly, possible role of Otog, Grwd1 and Abcc6 in resistance to TBEV remains to be elucidated.

Public database BioGPS shows that all the candidate genes are in uninfected mice expressed in tissues such as brain, spleen and liver (Table 2). Brain is the main target for the virus; however, during the extraneural phase of the infection, several tissues and organs in the body are infected, including spleen and liver [44]. Highest expression in these tissues exhibits Cd33 and SiglecE with expression in microglia ten times higher than median value (>10M), Cd33 and Klk1b22 are highly expressed in spleen (>3M), >10M expression of these two genes is also observed in bone marrow; SiglecE is also highly expressed in bone (>3M) and bone marrow macrophages (>3M), whereas Cd33 is highly expressed
## Table 1 List of candidate genes in TBEV susceptibility locus

| Position Bp | Reference genotype C57BL/6 | Genotype BALB/c | Genotype STS | Protein position of amino acid | Reference amino acid | Alteration Type of change | Gene symbol | Transcription status | Gene name | Gene ID: MGI | Gene ID: NCBI |
|-------------|-----------------------------|-----------------|--------------|-------------------------------|----------------------|--------------------------|-------------|---------------------|-----------|----------------|----------------|
| 43,528,893  | C/C                         | C/C             | T/T          | 353 G                        | K                    | Single AA Change          | Cd33        | KNOWN               | CD33 antigen | 99,440         | 12,489        |
| 43,532,167  | G/G                         | G/G             | A/A          | 190 R                        | *                    | Nonsense Mutation         | Cd33        | KNOWN               | CD33 antigen | 99,440         | 12,489        |
| 43,659,827  | G/G                         | G/G             | T/T          | 102 D                        | E                    | Single AA Change          | SiglecE     | KNOWN               | Salic acid binding Ig-like lectin E | 1,932,475   | 83,382        |
| 44,115,970  | A/A                         | A/A             | C/A          | 115 L                        | Y                    | Single AA Change          | Klk1b22     | KNOWN               | Kallikrein 1-related peptidase b22 | 95,291      | 13,646        |
| 44,140,534  | G/G                         | G/G             | C/C          | 76 G                         | A                    | Single AA Change          | Klk1b16     | KNOWN               | Kallikrein 1-related peptidase b16 | 891,982    | 16,615        |
| 45,650,779  | G/G                         | G/G             | A/A          | 190 R                        | W                    | Single AA Change          | Fut2        | KNOWN               | Fucosyltransferase 2 | 109,374     | 14,344        |
| 45,830,054  | CTCTTC                      | CTCTTCA         | C/C          | 129 ED                       | .                    | Deletion                  | Grwd1       | KNOWN               | Glutamate-rich WD repeat containing 1 | 2,141,989   | 101,612       |
| 45,977,290  | C/C                         | A/A             | C/C          | 1448 V                       | L                    | Single AA Change          | Abcc6       | KNOWN               | ATP-binding cassette sub-family C (CFTR/MRP), member 6 | 1,351,634   | 27,421        |
| 46,262,804  | C/C                         | T/T             | 748 R        | W                             | Single AA Change     | Otog         | KNOWN               | Otogelin    | 1,202,064 | 18,419        |
| 62,419,214  | C/C                         | CAGGCAATTGG     | C/C          | 275 P                        | PVPMP                | Insertion                | Mkrn3       | KNOWN               | Makorin, ring finger protein, 3 | 2,181,178   | 22,652        |

Table shows differences between BALB/c and STS in DNA and protein sequences in potential candidate genes. Table shows also sequences of the reference mouse strain C57BL/6.
## Table 2 Expression of potential candidate genes in organs and cells of uninfected mice

| Gene symbol | Cd33 | Siglece | Klk1b22 | Klk1b16 | Fut2 | Grwd1 | Abcc6 | Otog | Mkm3 |
|-------------|------|---------|---------|---------|------|-------|-------|-----|------|
| Gene ID: MGI | 99,440 | 1,932,475 | 95,291 | 891,982 | 109,374 | 2,141,989 | 1,351,634 | 1,202,064 | 2,181,178 |
| Gene ID: NCBI | 12,489 | 83,382 | 13,646 | 16,615 | 14,344 | 27,421 | 18,419 | 22,652 |
| Median | 5.2 | 4.7 | 4.6 | 4.6 | 4.9 | 163 | 46 | 4.95 | 4.8 |

### Organs

| Gene ID: MGI | Gene ID: NCBI | Median | Organs |
|--------------|--------------|--------|--------|
| Bone | >10M | 77.05 | Bone |
| Bone marrow | >10M | 114.05 | Bone marrow |
| Amygdala | ~M | 4.97 | Amygdala |
| Cerebellum | ~M | 4.91 | Cerebellum |
| Cerebral cortex | ~M | 4.91 | Cerebral cortex |
| Hippocampus | ~M | 4.91 | Hippocampus |
| Olfactory bulb | ~M | 4.89 | Olfactory bulb |
| Eye | ~3M | 13.71 | Eye |
| Lens | >M | 9.26 | Lens |
| Retina | ~M | 5.72 | Retina |
| Intestine large | <M | 4.86 | Intestine large |
| Intestine small | ~M | 4.91 | Intestine small |
| Kidney | ~M | 4.87 | Kidney |
| Lacrimal gland | ~M | 4.92 | Lacrimal gland |
| Liver | ~M | 4.89 | Liver |
| Lymph nodes | >3M | 85.8 | Lymph nodes |
| Pancreas | ~M | 7.40 | Pancreas |
| Pituitary | ~M | 4.89 | Pituitary |
| Prostate | ~M | 5.25 | Prostate |
| Salivary gland | ~M | 5.62 | Salivary gland |
| Spleen | ~3M | 15.39 | Spleen |
| Stomach | ~M | 4.89 | Stomach |
| Tests | ~M | 5.40 | Tests |
| Uterus | ~M | 4.91 | Uterus |

### Cells

| Gene symbol | Cd33 | Siglece | Klk1b22 | Klk1b16 | Fut2 | Grwd1 | Abcc6 | Otog | Mkm3 |
|-------------|------|---------|---------|---------|------|-------|-------|-----|------|
| Gene ID: MGI | 99,440 | 1,932,475 | 95,291 | 891,982 | 109,374 | 2,141,989 | 1,351,634 | 1,202,064 | 2,181,178 |
| Gene ID: NCBI | 12,489 | 83,382 | 13,646 | 16,615 | 14,344 | 27,421 | 18,419 | 22,652 |
| Median | 5.2 | 4.7 | 4.6 | 4.6 | 4.9 | 163 | 46 | 4.95 | 4.8 |

| Gene ID: MGI | Gene ID: NCBI | Median | Organs |
|--------------|--------------|--------|--------|
| B cells | >3M | 25.26 | B cells |
| Common myeloid progenitor | >M | 11.3 | Common myeloid progenitor |
| Dendritic lymphoid cells | >M | 9.83 | Dendritic lymphoid cells |
| Gene symbol                        | Cd33  | Siglece | Klk1b22 | Klk1b16 | Fut2  | Grwd1 | Abcc6 | Otag  | Mkm3  |
|-----------------------------------|------|--------|--------|--------|------|------|------|-------|-------|
| Dendritic cells myeloid CD8a−     | 77.51| 4.96   | ~M     | 4.64   | ~M   | 4.86 | ~M   | 299.19| ~M    | 4.95 | ~M   | 4.64 | ~M   |
| Dendritic plasmacytoid B220+     | 140.59| 4.74  | ~M     | 88.52  | >10M | 4.64 | ~M   | 238.95| >M    | 4.64 | ~M   | 5.14 | ~M   |
| Granulocytes macl + gr1+          | 651.27| 6.87  | >M     | 4.64   | ~M   | 5.04 | ~M   | 53.79 | <M   | 4.64 | ~M   | 4.95 | ~M   |
| Hematopoietic stem cells          | 42.14| 4.8    | ~M     | 4.96   | ~M   | 6.41 | >M   | 1445.80| ~10M | 4.64 | ~M   | 4.95 | ~M   |
| Macrophage_bone marrow            | 11.64| >M 1.46| >3M    | 4.64   | ~M   | 4.86 | ~M   | 308.83| >M    | 4.64 | ~M   | 4.95 | ~M   |
| Mast cells                        | 214.54| 4.67  | ~M     | 4.64   | ~M   | 4.83 | ~M   | 55.07 | <M   | 4.64 | ~M   | 4.95 | ~M   |
| Mega_erythrocyte progenitor       | 5.31 | ~M 4.67| ~M     | 7.57   | >M   | 6.47 | >M   | 2842.61| >10M | 4.64 | ~M   | 8.07 | >M   |
| Microglia                         | 99.81| >10M 79.64| >10M 4.64 | ~M     | 4.86 | ~M   | 269.08| >M    | 4.64 | ~M   | 4.95 | ~M   |
| Osteoclasts                       | 363.46| 4.77  | ~M     | 7.67   | >M   | 4.99 | ~M   | 327.07| >M    | 4.64 | ~M   | 5.31 | ~M   |
| T-cellsCD4+                       | 4.91 | ~M 5.00| ~M     | 7.57   | >M   | 4.82 | ~M   | 621.74| >3M   | 4.64 | ~M   | 5.06 | ~M   |
| T-cellsCD8+                       | 4.91 | ~M 4.67| ~M     | 13.55  | >3M  | 5.29 | ~M   | 715.19| >3M   | 4.64 | ~M   | 6.13 | >M   |
| T-cells FoxP3+                    | 25.67| >3M 4.67| ~M     | 4.64   | ~M   | 4.96 | ~M   | 584.63| ~3M   | 4.64 | ~M   | 4.95 | ~M   |

Data were compiled from public database BioGPS (http://biogps.org) May 6, 2018. First column: relative units; second column: relationship to median (M). M = median value across all samples for a single probe set.
in granulocytes (>30M), plasmacytoid dendritic cells (>30M), osteoclasts (>30M), myeloid dendritic cells (>10M), in spleen (>3M), lymph nodes (>3M), eye cup (>3M), B cells in marginal zone (>3M) and in FoxP3+ T cells (>3M). For both Klk1b22 and Klk1b16 is characteristic very high expression in salivary gland (>1000M) and high expression in lacrimal gland (>30M). Klk1b22 is also highly expressed in large intestine (>30M), kidney (>30M), pancreas (>30M), testis (>30M), stomach (>10M), plasmacytoid dendritic cells (>10M), small intestine (>3M), spleen (>3M) and CD8+ T cells (>3M), whereas Klk1b16 is also highly expressed in pituitary (>30M), kidney (>3M), pancreas (>3M) and testis (>30M). Highest expression of Fut2 was observed in uterus (>30M), and in stomach (>10M), it was also highly expressed in large intestine (>3M), prostate (>3M) and in testis (>3M). GRWD1 was described to play a role in ribosome biogenesis and during myeloid differentiation [45]. High expression level in hematopoietic stem cells (>10M), mega erythrocyte progenitors (>10M), granulocytes (>10M), common myeloid progenitor (>3M) supports this finding, but it is also expressed in several T cell subpopulations (>3M), B cells in marginal zone (>3M), as well as in lacrimal gland. Abcc6 is highly expressed in liver (>30M) and in lens (>10M) and Mrkn3 is highly expressed in retina (10M) and in oil factory bulb (>3M). The expression data further support a potential role of detected candidate genes in defense against TBEV, but they must be in the future complemented with data describing gene expression after TBEV infection. We have found a susceptibility allele of a locus on chromosome 7 in the resistant strain STS. This apparent paradox is likely caused by the fact that most inbred mouse strains were produced without an intentional selective breeding for a specific quantitative phenotype (like susceptibility to specific infections). Therefore they inherited randomly from their non-inbred ancestors susceptible alleles at some loci and resistant alleles at others, so that their overall susceptibility phenotype depends on the relative number of both types of alleles. Such finding is not unique, as susceptibility alleles originating from resistant strains were found in susceptibility studies of other infectious diseases [17, 46, 47] and colon cancer [48]. Similarly, in different in vitro tests of immune responses a low-responder allele was identified in a high responding strain [49] or vice versa [50]. Another explanation might be presence of BALB/c allele interacting with STS allele on chromosome 7. Demonstration of such interaction would require further experiments. We have already observed interaction of STS and BALB/c alleles leading to extreme phenotypes in susceptibility to L. major [51] and L. tropica [47].

Conclusion

Mapping of TBEV controlling genes in mice is not easy due to presence of a strong TBEV controlling gene Oas1b, which is identical both in BALB/c and CcS-11, as well as in majority of laboratory mouse strains [6, 7] and masks effects of other controlling genes. Therefore using a powerful genetic system—recombinant congenic strains, we succeeded in mapping novel TBEV susceptibility locus on chromosome 7 and identified 9 potential candidate genes. Products of some of these genes have been described to participate in defense against flaviviruses, the role of the others is unknown. The genes detected here will be focus of future studies that will include characterization of candidate gene(s) products in BALB/c and CcS-11, introducing modification to candidate genes and study their influence on disease outcome in mouse, and study influence of polymorphisms in human orthologs of candidate genes on susceptibility to TBEV in humans.

List of abbreviations

Abcc6 (ATP-binding cassette, sub-family C (CFTR/MRP), member 6), mouse gene; ABCCC6-human gene; ABCC6-protein (gene product); Ccr5: chemokine (C–C motif) receptor 5; Cd209: CD209 antigen; Cd33 (CD33 antigen); Fut2 (fucosyltransferase 2); Grwd1 (glutamate-rich WD repeat containing 1); Ifnl3: interferon lambda 3 (synonym Il28b); Il10: interleukin 10; Klk1b16 (kallikrein 1-related peptidase b16); Klk1b22 (kallikrein 1-related peptidase b22); Mrkn3 (makorin, ring finger protein, 3); Oas1b: 2′-5′-oligoadenylate synthetase gene; Otog (otogelin); pfu: Plaque-forming unit; RC: Recombinant congenic; s.c: Subcutaneous; Siglec (sialic acid binding Ig-like lectin E); TBE: Tick-borne encephalitis; TBEV: Tick-borne encephalitis virus; Tlr3: toll-like receptor 3.

According to current gene and protein nomenclature, mouse gene symbols are italicized, with only the first letter in upper-case (e.g. Cd33). Protein symbols are not italicized, and all letters are in upper-case (e.g. CD33). Human gene symbols are in upper-case and are italicized (e.g. CD33). Protein symbols are identical to their corresponding gene symbols except that they are not italicized (e.g. CD33).

Authors’ contributions

ML conceived and designed the research, analyzed the experiments, coordinated collaborations; and wrote the manuscript. MP, YS, MŠ, DR, VV, JV, LM, JS and MS performed the experiments and participated in the design of experiments and analysis of data. HS performed sequence analysis. KWB performed statistical analysis. HS and JV analyzed bioinformatics data. All authors read and approved the final manuscript.

Author details

1 Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Braničovská 31, 37005 České Budějovice, Czech Republic. 2 Department of Virology, Veterinary Research Institute, Hudcova 70, 62100 Brno, Czech Republic. 3 Department of Molecular and Cellular Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 57, 35001 Brno, Czech Republic. 4 Department of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 57, 35001 Brno, Czech Republic. 5 Institute of Virology, Veterinary Research Institute, Hudcova 70, 62100 Brno, Czech Republic. 6 Department of Molecular and Cellular Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 57, 35001 Brno, Czech Republic.
1. Dobler G, Gniel D, Petermann R, Pfeffer M. Epidemiology and distribution of tick-borne encephalitis virus infection in Europe—overview.  Ticks Tick Borne Dis.  2011;2:64–76.

2. Süß J. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia—an overview. Ticks Tick Borne Dis.  2011;2:2–15.

3. Barkhash AV, Perelygin AA, Babenko VN, Myasnikova NG, Pilipenko PI, Rosomaschenko AG, Voevoda MI, Brinton MA. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA.  2002;99(14):9322–7.

4. Rushon JD, Lecollinet S, Hübäle Z, Svobodová P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

5. Perelygin AA, Scherbak SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Association of single nucleotide polymorphisms in the promoter region of the CD209 gene with tick-borne encephalitis virus infection. J Infect Dis.  2010;202:1813–8.

6. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi PE, Deubevé V, Guenet JL, Despres P. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci USA.  2002;99(11):11311–6.

7. Darrell MB, Koprowski H. Genetically determined resistance to infection with group B arboviruses. I. Distribution of the resistance gene among various mouse populations and characteristics of gene expression in vivo. J Infect Dis.  1974;129(3):240–7.

8. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Fape J, Foster GA, Kyszytz D, Follmann D, Stamner SL, Margolis LB, Murphy PM. Genetic variation inQNALT is a risk factor for initial infection with West Nile virus in man. PLoS Pathog.  2009;5(2):e1000321.

9. Turtle L, Griffiths MJ, Solomon T. Encephalitis caused by flaviviruses. QJM.  2012;105:219–23.

10. Barkhash AV, Perelygin AA, Babenko VN, Brinton MA, Voevoda MI. Single nucleotide polymorphism in the promoter region of the CD209 gene is associated with human predisposition to severe forms of tick-borne encephalitis. Antivir Res.  2012;93:64–8.

11. Kindberg E, Mikienni A, Av C, Akerblad D, Vener S, Swedenlund L, Lundkvist A, Svensson L. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tick-borne encephalitis. J Infect Dis.  2008;197:266–9.

12. Barkhash AV, Voevoda MI, Rosomaschenko AG. Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population. Antivir Res.  2013;99(2):136–8.

13. Mikienni A, Pakalniene J, Nordgren J, Carlsson B, Hagbom M, Svensson L, Lindquist L. Polymorphisms in chemokine receptor 5 and toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population. PLoS ONE.  2014;9(9):e106798.

14. Barkhash AV, Babenko VN, Voevoda MI, Rosomaschenko AG. Association of IL28B and IL10 gene polymorphism with predisposition to tick-borne encephalitis in a Russian population. Ticks Tick Borne Dis.  2016;7(5):808–12.

15. Dément P, Hart AA. Recombinant congenic strains—a new tool for analyzing genetic traits determined by more than one gene. Immunogenetics.  1996;46(6):416–22.

16. Palus M, Vojtíšková J, Salat J, Kopček J, Grubhoffer L, Lipoldová M, Demant P, Růžek D. Mice with different susceptibility to tick-borne encephalitis virus infection show selective neutralizing antibody response and inflammatory response in the central nervous system. J Neuroinflammation.  2013;10:77.

17. Slapničková M. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

18. Rushon JD, Lecollinet S, Hubalek Z, Svobodova P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

19. Rushon JD, Lecollinet S, Hubalek Z, Svobodova P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

20. Rushon JD, Lecollinet S, Hubalek Z, Svobodova P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

21. Rushon JD, Lecollinet S, Hubalek Z, Svobodova P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

22. Rushon JD, Lecollinet S, Hubalek Z, Svobodova P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

23. Rushon JD, Lecollinet S, Hubalek Z, Svobodova P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.

24. Rushon JD, Lecollinet S, Hubalek Z, Svobodova P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria. Emerg Infect Dis.  2011;17:635–9.
26. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttmann M, Lander ES, Getz G,Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.
27. Macauley MS, Crockern PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14(10):653–66.
28. Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varke A. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol. 2003;23(12):4199–206.
29. Gricicu A, Serrano-Pozo A, Parrado AR, Lesinski AN, Mullin K, Hooil B, Choi SH, Hyman BT, Tanze RE. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid β. Neuron. 2013;78(4):631–43.
30. Jiang T, Yu JT, Hu N, Tan MS, Zhu XC, Tan L. CD33 in Alzheimer’s disease. Mol Neurobiol. 2014;49(1):529–35.
31. Claude J, Linnartz-Gerlach B, Kudin AP, Kunz WS, Neumann H. Microglial CD33-related Siglec-E inhibits neurotoxicity by preventing the phagocytosis-associated oxidative burst. J Neurosci. 2013;33(46):18270–6.
32. Kant Upadhyay R. Biomarkers in Japanese encephalitis: a review. Biomed Res Int. 2013;2013:591290.
33. Rust NM, Papa MP, Scovino AM, da Silva MM, Calzavara-Silva CE, Marques ET Jr, Peçanha LM, Scharfstein J, Arruda LB. Bradykinin enhances Sindbis virus infection in human brain microvascular endothelial cells. Virology. 2012;422(1):81–91.
34. Nico D, Feijó DF, Maran N, Morrot A, Scharfstein J, Palatnik-de Arruda LB, Nagajyothi F, Granato D. Microglial bradykinin B2 receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. PLoS Pathog. 2007;3(11):e185.
35. Kurey I, Kobets T, Havelková H, Badalová J, Svobodová M, Vladimirov I, Jarošíková V, Lipoldová M. Different genetic control of cutaneous and visceral disease after Leishmania major infection in mice. Infect Immun. 2003;71:2041–6.
36. Sohrabi Y, Havelková H, Kobets T, Šíma M, Volkova V, Grekov I, Jarolíšková T, Kurey I, Vojtíšková J, Svobodová M, Demant P, Lipoldová M. Mapping the genes for susceptibility and response to Leishmania tropica in mouse. PLoS Negl Trop Dis. 2013;7(7):e2282.
37. van Wezel T, Stassen AP, Moen CJ, Hart AA, van der Valk MA. 2011;29(1):24–6.
38. Mottram L, Wiklund G, Larson G, Qadri F, Svennerholm AM. FUT2 non-secretor status is associated with altered susceptibility to symptomatic enterotoxigenic Escherichia coli infection in Bangladeshi. Sci Rep. 2017;7(1):10649.
39. Magalhães A, Rossez Y, Robbe-Masselot C, Maes E, Gomes J, Shevtsova A, Bugaytsova J, Borel T, Reis CA. MucSac gastric mucin glycosylation is shaped by FUT2 activity and functionally impacts Helicobacter pylori binding. Sci Rep. 2016;6:25575.
40. Ko A, Lee EW, Yeh YJ, Yang MR, Oh W, Moon JS, Song J. MKRN1 induces degradation of West Nile virus capsid protein by functioning as an E3 ligase. J Virol. 2010;84(1):426–36.
41. http://www.informatics.jax.org/genes.shtml. Accessed 5 Sept 2017.
42. Hayasaka D, Aoki K, Morita K. Development of simple and rapid assay to detect viral RNA of tick-borne encephalitis virus by reverse transcription-loop-mediated isothermal amplification. Virol J. 2013;10:68.
43. Gratenstein K, Heggstad AD, Fortun J, Notterpek L, Fletcher BS. The WD-repeat protein GRWD1: potential roles in myeloid differentiation and ribosome biogenesis. Genomics. 2005;89(6):762–73.
44. Vladimirov V, Badalová J, Svobodová M, Havelková H, Hart AA, Blazková H, Demant P, Lipoldová M. Different genetic control of cutaneous and visceral disease after Leishmania major infection in mice. Infect Immun. 2003;71:2041–6.
45. Sohrabi Y, Havelková H, Kobets T, Šíma M, Volkova V, Grekov I, Jarolíšková T, Kurey I, Vojtíšková J, Svobodová M, Demant P, Lipoldová M. Mapping the genes for susceptibility and response to Leishmania tropica in mouse. PLoS Negl Trop Dis. 2013;7(7):e2282.
46. van Wezel T, Stassen AP, Moen CJ, Hart AA, van der Valk MA, Demant P. Gene interaction and single gene effects in colon tumour susceptibility in mice. Nat Genet. 1996;14:468–70.
47. Lipoldová M, Havelková H, Badalová J, Vojtíšková J, Quan L, Krulova M, Sohrabi Y, Stassen AP, Demant P. Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility. Cancer Immunol Immunother. 2010;59:203–15.
48. Kosalová M, Havelková H, Krulová M, Demant P, Lipoldová M. The production of two Th2 cytokines, interleukin-4 and interleukin-10, is controlled independently by loci Cypr1 and by loci Cypr2 and Cypr3, respectively. Immunogenetics. 1999;49:134–41.
49. Havelková H, Badalová J, Svobodová M, Vojtíšková J, Kurey I, Vladimirov V, Demant P, Lipoldová M. Genetics of susceptibility to leishmaniasis in mice: four novel loci and functional heterogeneity of gene effects. Genes Immun. 2006;7(3):220–33.